Autologous Immunomagnetic Selected cd133+ Cells in the Treatment of No-option Critical Limb Ischemia: Clinical and Ceus Assessed Results. View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2009-2011

ABSTRACT

Aim: to value the safety and efficacy of local intramuscular administration of immunoselected autologous endothelial progenitor cells in the treatment of critical limb ischemia in patients without revascularization options. Primary goal: to value the feasibility of mobilization, harvesting, immunoselection and auto transplantation of endothelial progenitor cells. Secondary goal: to value the efficacy of local administration of autologous endothelial progenitor cells in the treatment of critical limb ischemia Detailed Description Type of the study. Prospective single centre not randomized. Aim of the study. To assess the safety, feasibility and efficacy of local intramuscular administration of autologous selected CD 133+ cells in patients suffering from CLI. All the patients enrolled were suffering from CLI according to the TASC 2 definitions and had no revascularization option, on the basis of contrast CT or angiography imaging. A detailed informed consent, approved by our EC, had been required. An age lower than 18 years and upper than 70 years because of a poor marrow responsiveness to drug simulation in elderly people Clinical unsteadiness of the CLI, such as gangrene requiring major amputation and a poor life expectancy were introduced as exclusion criteria for supposed latency of the EPCs action. Severe systemic illness was judged to increase the risk of the marrow stimulation. Patients with allergic diathesis, child-bearing age, previous EPCs muscular implant, previous medical experimental protocol and any conflict of interest with the study were excluded. Patients: we enroll patients with a history of Rutherford stage 4 (rest pain) or 5 (small ischemic lesions) PAD. All the patients have previous (contrast CT, MR or angiography) vascular imaging excluding revascularization options, both endovascular and open and encountered the enrolment and exclusion criteria. Every patient undergo routine physical and instrumental examination including electrocardiogram, chest X-ray and blood sample analysis. Younger patients met the Buerger disease criteria, whereas others had pure atherosclerotic lesions. CEUS Imaging Protocol. Two operators (F.C. and A.G., with 20 and 3 years experience, respectively) who are blinded to treatment perform contrast-enhanced US for all patients. Two US scanner (Philips iU22 (Bothell, WA, USA) with linear array L9-3 transducer and GE Logiq e9 (GE Healthcare, Milwaukee, WI, USA) with linear array L6-9 transducer are used. The imaging parameters are: reduced transmit power (mechanical index <0.06), at approximately 7-10 frames per second and one focus well below the level of the target to ensure a more uniform pressure field. Dual-mode presentation of a grayscale image side-by-side with the contrast image facilitated real-time identification of anatomic structures and ROI selection. Image loops of approximately 60 seconds were acquired. Effort was made to have a uniform gain across the image and to avoid gain saturation. The TGC (time gain compensation) was set such that before contrast arrival a uniform black image was shown. A vial of contrast agent (SonoVue BR1; Bracco, Milan, Italy) is prepared at a concentration of about 2x108 sulfur hexafluoride-filled microbubbles per milliliter, according to the manufacturer's recommendations. Prior to each injection, microbubbles are resuspended by shaking the vial. The position of the probe is recorded for each patient in order to maintain the same position during follow up. The contrast injection consists of an intravenous bolus of 4.8 ml of contrast agent injected in antecubital vein in 2 seconds followed by a saline flush of 5 ml. The injection is made with the patient supine and after 10 minute of rest to avoid exercise related micro-vascular dilatation. The radiologist maintains a constant image plane with the aid of the tissue (fundamental image) of the "Contrast Side/Side" imaging mode. Image analysis. The image loops are transferred to a personal computer for further analysis. The main image analysis tasks are: a) identification of tibialis anterior artery (TAA) area, b) selection of a representative region of normal tibialis anterior muscle (TAM) and c) formulation of time-intensity curves. Two manually defined region of interest (ROI), 2 cm and 4 cm sided-squares, are placed, respectively, over the tibialis anterior muscle with no evidence of arterial branches, over tibialis anterior artery and over a small tibialis arterial branch. The ROIs are placed in the same anatomical position for each patient to avoid unwanted differences during follow up examinations. A time/intensity curve (TIC) is obtained for each ROI. From an analysis of CEUS time-intensity curves, we compute regional blood flow (RBF) and volume (RBV). Time-intensity curves are extracted using commercial quantification software (QontraXt v.3.60, AMID, Rome, Italy). This software allows manual region of interest (ROI) selection, measurement of the selected ROI area and provides linear data for the time-intensity curves. For the ROI in the normal ATM effort is made to place the region in an area without large vessels. The ROI of the ATA is a 2 cm square area and the ATM ROI is a 4 cm square area. Time-intensity curves are obtained by computing the mean intensity of pixels comprised within the ROI at each time point. For each image loop are calculated: - RBV which consists in the total amount of contrast media within the selected ROI, in a period of time. Due to the characteristics of US contrast media, it reflects the quantity of blood in a defined region. It is directly related to the area under the curve (AUC). - RBF that is in direct ratio to perfusion in a given ROI. It consist in the Contrast Media flow (related to the Blood Flow) in a selected ROI. It is related to the Mean Transit Time. Marrow stimulation. Human recombinant granulocyte colony-stimulating factor (rhGCSF) is administered subcutaneously for 4-5 consecutive days at a dosage of 10 µg/kg daily, split in 2 doses. Starting from the third day of mobilization, the CD133+ cell count is monitored daily by cytofluorimetric analysis on a 2 ml sample obtained from the patients' peripheral blood. The minimum CD133+ cell count acceptable for leukapheresis (LKF) collection was 10/µl. Patients are monitored for any G-CSF related side effects. Leukapheresis collection. A single LKF collection is planned for each patient using a third generation cell separator device (Spectra Cobe, Lakewood, CO), processing at least 2.5 blood volumes according to our internal protocol for stem cell collection. Patients are monitored for blood pressure and heart rate during the entire collection procedure. Immediately after LKF a sample from patient's peripheral blood is taken for haemocytometric analysis to evaluate platelet count and Hb levels. Each leukapheresis collection is diluted with 10% acide citrate dextrose (ACD-A) and maintains overnight at 4°C before immunomagnetic cell selection. A sample of 2 ml from each LKF bag is taken for cytofluorimetric analysis. Four hours after LKF collection coagulation parameters, electrolyte levels and hemocytometric analysis is evaluated. Immunomagnetic cell selection. CD133 immunomagnetic cell selections are performed the day after LKF collection using the Clini-MACS (Miltenyi Biotec) device according to the manufacturer's standard protocol. Briefly, CliniMACS CD133 reagent (formed by super paramagnetic particles composed of iron oxide and dextran conjugated to murine monoclonal antibodies) is added to the cells for incubation. The product is subsequently washed by dilution with buffer (CliniMACS PBS-EDTA buffer supplemented with 0.5% human serum albumin) and the cell bag is hung on the device for the automated selection of CD133 labeled cells. A sample of 2 ml from the positive fraction is taken for cytofluorimetric analysis. Quality controls. Clonogenic assays. A sample taken from the CD133 cell positive fraction after each immunomagnetic cell selection procedure is seeded for short term (14 days) clonogenic assays. A standard mixture of methylcellulose plus recombinant human erythropoietin, rh stem cell factor (SCF), rhGM-CSF, and rh interleukin-3 (IL-3) is employed (Stem Cell Technologies, Vancouver, BC, Canada; MACS Media, Miltenyi Biotec GmbH, Bergisch Gladbach,Germany). Microbial cultures. Microbial cultures on the immunoselection waste bag containing the negative fraction are carried out to detect aerobic-anaerobic bacteria and fungal contamination. A sample of 10ml is inoculated in the culture medium (Bact/Alert FA and BacT/Alert FN, Organon Teknika Corp., Durham, NC) and incubated for 10 days at 37°C. Cytofluorimetric analysis. Samples obtained from peripheral blood before mobilization with G-CSF, at time of leukapheresis and after immunomagnetic cell selection are analyzed by flow cytometry to evaluate the expression of specific stem cell and endothelial antigens. Becton Dickinson FACSCanto was employed for all flow cytometric assays with a lyse no-wash technique, using the following monoclonal antibodies: anti-CD45 fluorescein isothiocyanate (FITC) (Becton Dickinson, San Jose, CA), anti-CD34 Peridinin-chlorophyll-protein complex (PerCP) (8G12 clone, Becton Dickinson), anti-CD133 phycoerythrin (PE) (AC133 clone, Miltenyi Biotec) and anti-VEGF-R2 allophycocyanin (APC) (R&D systems). Whole blood is processed following the instructions for VEGF-R2 (KDR) determination. Each blood sample is transferred to a 50 ml falcon tube and brought to a total volume of 30 ml by adding ammonium phosphate containing lysis buffer (Becton Dickinson). After a lysis period of 5 minutes PB is centrifuged at 500g for 5 minutes and washed two times with PBS containing 0,5% bovine serum albumin (BSA). 100 µl of each sample are then transferred in a BD tube for cytometric analysis and incubated for 15 minutes with 1µg/105 cells IgG in order to block all nonspecific sites. 50 µl of the IgG blocked sample are incubated with 20 µl of anti-VEGF-R2 antibody for 30 minutes at 4°C in the dark and then washed twice with PBS. At the end of the last wash step, 10 µl of each of the other antibodies (anti-CD45, anti-CD34, anti-CD133) are added and incubated 10 minutes at room temperature in the dark. Each sample is acquired with BD FACSCanto recording 100.000 events inside the lymphocyte plus monocyte gate. Data files are analyzed with FACS Diva 6.1 software. Viability is assessed using 7-amino-actinomycin D (7-AAD) (Molecular Probes, Eugene, OR). A sample for Hill and EBM2 clonogenic assays is taken from patient's peripheral blood before and after mobilization (at time of LKF collection). Implant procedure. After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot. Baseline assessment and follow up. Pain assessment is carried out with a personal scale of 3 degrees (mild, moderate and severe) and the pain killing drugs use monitoring. Ischemic lesions are treated weekly by a wound management skilled nurse. Preoperative and at 3, 6 and 12 months after the implant are assessed CEUS, lesion evolution and pain management. More... »

URL

https://clinicaltrials.gov/show/NCT01595776

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Aim: to value the safety and efficacy of local intramuscular administration of immunoselected autologous endothelial progenitor cells in the treatment of critical limb ischemia in patients without revascularization options. Primary goal: to value the feasibility of mobilization, harvesting, immunoselection and auto transplantation of endothelial progenitor cells. Secondary goal: to value the efficacy of local administration of autologous endothelial progenitor cells in the treatment of critical limb ischemia\n\nDetailed Description\nType of the study. Prospective single centre not randomized. Aim of the study. To assess the safety, feasibility and efficacy of local intramuscular administration of autologous selected CD 133+ cells in patients suffering from CLI. All the patients enrolled were suffering from CLI according to the TASC 2 definitions and had no revascularization option, on the basis of contrast CT or angiography imaging. A detailed informed consent, approved by our EC, had been required. An age lower than 18 years and upper than 70 years because of a poor marrow responsiveness to drug simulation in elderly people Clinical unsteadiness of the CLI, such as gangrene requiring major amputation and a poor life expectancy were introduced as exclusion criteria for supposed latency of the EPCs action. Severe systemic illness was judged to increase the risk of the marrow stimulation. Patients with allergic diathesis, child-bearing age, previous EPCs muscular implant, previous medical experimental protocol and any conflict of interest with the study were excluded. Patients: we enroll patients with a history of Rutherford stage 4 (rest pain) or 5 (small ischemic lesions) PAD. All the patients have previous (contrast CT, MR or angiography) vascular imaging excluding revascularization options, both endovascular and open and encountered the enrolment and exclusion criteria. Every patient undergo routine physical and instrumental examination including electrocardiogram, chest X-ray and blood sample analysis. Younger patients met the Buerger disease criteria, whereas others had pure atherosclerotic lesions. CEUS Imaging Protocol. Two operators (F.C. and A.G., with 20 and 3 years experience, respectively) who are blinded to treatment perform contrast-enhanced US for all patients. Two US scanner (Philips iU22 (Bothell, WA, USA) with linear array L9-3 transducer and GE Logiq e9 (GE Healthcare, Milwaukee, WI, USA) with linear array L6-9 transducer are used. The imaging parameters are: reduced transmit power (mechanical index <0.06), at approximately 7-10 frames per second and one focus well below the level of the target to ensure a more uniform pressure field. Dual-mode presentation of a grayscale image side-by-side with the contrast image facilitated real-time identification of anatomic structures and ROI selection. Image loops of approximately 60 seconds were acquired. Effort was made to have a uniform gain across the image and to avoid gain saturation. The TGC (time gain compensation) was set such that before contrast arrival a uniform black image was shown. A vial of contrast agent (SonoVue BR1; Bracco, Milan, Italy) is prepared at a concentration of about 2x108 sulfur hexafluoride-filled microbubbles per milliliter, according to the manufacturer's recommendations. Prior to each injection, microbubbles are resuspended by shaking the vial. The position of the probe is recorded for each patient in order to maintain the same position during follow up. The contrast injection consists of an intravenous bolus of 4.8 ml of contrast agent injected in antecubital vein in 2 seconds followed by a saline flush of 5 ml. The injection is made with the patient supine and after 10 minute of rest to avoid exercise related micro-vascular dilatation. The radiologist maintains a constant image plane with the aid of the tissue (fundamental image) of the \"Contrast Side/Side\" imaging mode. Image analysis. The image loops are transferred to a personal computer for further analysis. The main image analysis tasks are: a) identification of tibialis anterior artery (TAA) area, b) selection of a representative region of normal tibialis anterior muscle (TAM) and c) formulation of time-intensity curves. Two manually defined region of interest (ROI), 2 cm and 4 cm sided-squares, are placed, respectively, over the tibialis anterior muscle with no evidence of arterial branches, over tibialis anterior artery and over a small tibialis arterial branch. The ROIs are placed in the same anatomical position for each patient to avoid unwanted differences during follow up examinations. A time/intensity curve (TIC) is obtained for each ROI. From an analysis of CEUS time-intensity curves, we compute regional blood flow (RBF) and volume (RBV). Time-intensity curves are extracted using commercial quantification software (QontraXt v.3.60, AMID, Rome, Italy). This software allows manual region of interest (ROI) selection, measurement of the selected ROI area and provides linear data for the time-intensity curves. For the ROI in the normal ATM effort is made to place the region in an area without large vessels. The ROI of the ATA is a 2 cm square area and the ATM ROI is a 4 cm square area. Time-intensity curves are obtained by computing the mean intensity of pixels comprised within the ROI at each time point. For each image loop are calculated: - RBV which consists in the total amount of contrast media within the selected ROI, in a period of time. Due to the characteristics of US contrast media, it reflects the quantity of blood in a defined region. It is directly related to the area under the curve (AUC). - RBF that is in direct ratio to perfusion in a given ROI. It consist in the Contrast Media flow (related to the Blood Flow) in a selected ROI. It is related to the Mean Transit Time. Marrow stimulation. Human recombinant granulocyte colony-stimulating factor (rhGCSF) is administered subcutaneously for 4-5 consecutive days at a dosage of 10 \u00b5g/kg daily, split in 2 doses. Starting from the third day of mobilization, the CD133+ cell count is monitored daily by cytofluorimetric analysis on a 2 ml sample obtained from the patients' peripheral blood. The minimum CD133+ cell count acceptable for leukapheresis (LKF) collection was 10/\u00b5l. Patients are monitored for any G-CSF related side effects. Leukapheresis collection. A single LKF collection is planned for each patient using a third generation cell separator device (Spectra Cobe, Lakewood, CO), processing at least 2.5 blood volumes according to our internal protocol for stem cell collection. Patients are monitored for blood pressure and heart rate during the entire collection procedure. Immediately after LKF a sample from patient's peripheral blood is taken for haemocytometric analysis to evaluate platelet count and Hb levels. Each leukapheresis collection is diluted with 10% acide citrate dextrose (ACD-A) and maintains overnight at 4\u00b0C before immunomagnetic cell selection. A sample of 2 ml from each LKF bag is taken for cytofluorimetric analysis. Four hours after LKF collection coagulation parameters, electrolyte levels and hemocytometric analysis is evaluated. Immunomagnetic cell selection. CD133 immunomagnetic cell selections are performed the day after LKF collection using the Clini-MACS (Miltenyi Biotec) device according to the manufacturer's standard protocol. Briefly, CliniMACS CD133 reagent (formed by super paramagnetic particles composed of iron oxide and dextran conjugated to murine monoclonal antibodies) is added to the cells for incubation. The product is subsequently washed by dilution with buffer (CliniMACS PBS-EDTA buffer supplemented with 0.5% human serum albumin) and the cell bag is hung on the device for the automated selection of CD133 labeled cells. A sample of 2 ml from the positive fraction is taken for cytofluorimetric analysis. Quality controls. Clonogenic assays. A sample taken from the CD133 cell positive fraction after each immunomagnetic cell selection procedure is seeded for short term (14 days) clonogenic assays. A standard mixture of methylcellulose plus recombinant human erythropoietin, rh stem cell factor (SCF), rhGM-CSF, and rh interleukin-3 (IL-3) is employed (Stem Cell Technologies, Vancouver, BC, Canada; MACS Media, Miltenyi Biotec GmbH, Bergisch Gladbach,Germany). Microbial cultures. Microbial cultures on the immunoselection waste bag containing the negative fraction are carried out to detect aerobic-anaerobic bacteria and fungal contamination. A sample of 10ml is inoculated in the culture medium (Bact/Alert FA and BacT/Alert FN, Organon Teknika Corp., Durham, NC) and incubated for 10 days at 37\u00b0C. Cytofluorimetric analysis. Samples obtained from peripheral blood before mobilization with G-CSF, at time of leukapheresis and after immunomagnetic cell selection are analyzed by flow cytometry to evaluate the expression of specific stem cell and endothelial antigens. Becton Dickinson FACSCanto was employed for all flow cytometric assays with a lyse no-wash technique, using the following monoclonal antibodies: anti-CD45 fluorescein isothiocyanate (FITC) (Becton Dickinson, San Jose, CA), anti-CD34 Peridinin-chlorophyll-protein complex (PerCP) (8G12 clone, Becton Dickinson), anti-CD133 phycoerythrin (PE) (AC133 clone, Miltenyi Biotec) and anti-VEGF-R2 allophycocyanin (APC) (R&D systems). Whole blood is processed following the instructions for VEGF-R2 (KDR) determination. Each blood sample is transferred to a 50 ml falcon tube and brought to a total volume of 30 ml by adding ammonium phosphate containing lysis buffer (Becton Dickinson). After a lysis period of 5 minutes PB is centrifuged at 500g for 5 minutes and washed two times with PBS containing 0,5% bovine serum albumin (BSA). 100 \u00b5l of each sample are then transferred in a BD tube for cytometric analysis and incubated for 15 minutes with 1\u00b5g/105 cells IgG in order to block all nonspecific sites. 50 \u00b5l of the IgG blocked sample are incubated with 20 \u00b5l of anti-VEGF-R2 antibody for 30 minutes at 4\u00b0C in the dark and then washed twice with PBS. At the end of the last wash step, 10 \u00b5l of each of the other antibodies (anti-CD45, anti-CD34, anti-CD133) are added and incubated 10 minutes at room temperature in the dark. Each sample is acquired with BD FACSCanto recording 100.000 events inside the lymphocyte plus monocyte gate. Data files are analyzed with FACS Diva 6.1 software. Viability is assessed using 7-amino-actinomycin D (7-AAD) (Molecular Probes, Eugene, OR). A sample for Hill and EBM2 clonogenic assays is taken from patient's peripheral blood before and after mobilization (at time of LKF collection). Implant procedure. After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot. Baseline assessment and follow up. Pain assessment is carried out with a personal scale of 3 degrees (mild, moderate and severe) and the pain killing drugs use monitoring. Ischemic lesions are treated weekly by a wound management skilled nurse. Preoperative and at 3, 6 and 12 months after the implant are assessed CEUS, lesion evolution and pain management.", 
    "endDate": "2011-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01595776", 
    "keywords": [
      "cell", 
      "option", 
      "critical limb ischemia", 
      "CEUS", 
      "safety", 
      "efficacy", 
      "intramuscular", 
      "endothelial progenitor cell", 
      "patient", 
      "revascularization", 
      "primary goal", 
      "feasibility", 
      "mobilization", 
      "harvesting", 
      "immunoselection", 
      "transplantation", 
      "secondary goal", 
      "local administration", 
      "detailed description", 
      "single center", 
      "definition", 
      "contrast", 
      "angiography", 
      "informed consent", 
      "EC", 
      "age", 
      "responsiveness", 
      "simulation", 
      "elderly people", 
      "gangrene", 
      "amputation", 
      "life expectancy", 
      "exclusion criterion", 
      "latency", 
      "EPCs", 
      "systemic illness", 
      "risk", 
      "stimulation", 
      "child-bearing age", 
      "implant", 
      "experimental protocol", 
      "conflict", 
      "history", 
      "Rutherford", 
      "rest", 
      "ischemic lesion", 
      "pad", 
      "MR", 
      "vascular imaging", 
      "enrollment", 
      "examination", 
      "Electrocardiography", 
      "chest x-ray", 
      "sample analysis", 
      "Younger", 
      "criterion", 
      "atherosclerotic lesion", 
      "imaging protocol", 
      "operator", 
      "scanner", 
      "Philip", 
      "WA", 
      "USA", 
      "linear array", 
      "transducer", 
      "Ge", 
      "GE Healthcare", 
      "Milwaukee", 
      "WI", 
      "imaging parameter", 
      "power", 
      "index", 
      "frame", 
      "target", 
      "pressure field", 
      "dual mode", 
      "side-by-side", 
      "real-time identification", 
      "anatomic structure", 
      "selection", 
      "loop", 
      "uniform", 
      "saturation", 
      "Time", 
      "vial", 
      "contrast agent", 
      "Milan", 
      "Italy", 
      "Attention", 
      "microbubbles", 
      "manufacturer", 
      "recommendation", 
      "injection", 
      "probe", 
      "same position", 
      "bolus", 
      "vein", 
      "saline", 
      "dilatation", 
      "radiologist", 
      "image plane", 
      "tissue", 
      "fundamental", 
      "imaging mode", 
      "image analysis", 
      "Microcomputer", 
      "artery", 
      "representative", 
      "muscle", 
      "formulation", 
      "intensity", 
      "region interest", 
      "region of interest", 
      "cm", 
      "square", 
      "evidence", 
      "branch", 
      "difference", 
      "curve", 
      "regional blood flow", 
      "volume", 
      "quantification", 
      "Rome", 
      "software", 
      "measurement", 
      "ATM", 
      "large vessel", 
      "pixel", 
      "time point", 
      "total amount", 
      "contrast medium", 
      "period", 
      "characteristic", 
      "quantity", 
      "blood", 
      "defined region", 
      "area under the curve", 
      "ratio", 
      "perfusion", 
      "flow", 
      "blood flow", 
      "mean transit time", 
      "Granulocyte Colony-Stimulating Factor", 
      "dosage", 
      "dose", 
      "CD133+ cell", 
      "sample", 
      "peripheral blood", 
      "collection", 
      "side effect", 
      "leukapheresis", 
      "third generation", 
      "CO", 
      "processing", 
      "blood volume", 
      "protocol", 
      "stem cell", 
      "blood pressure", 
      "heart rate", 
      "collection procedure", 
      "platelet count", 
      "Hb", 
      "ACD", 
      "cell selection", 
      "bag", 
      "coagulation", 
      "electrolyte", 
      "Equipment and Supply", 
      "standard protocol", 
      "CD133", 
      "reagent", 
      "particle", 
      "iron oxide", 
      "dextran", 
      "murine monoclonal antibody", 
      "incubation", 
      "product", 
      "dilution", 
      "buffer", 
      "human serum albumin", 
      "labeled cell", 
      "fraction", 
      "quality control", 
      "clonogenic assay", 
      "selection procedure", 
      "short term", 
      "mixture", 
      "methylcellulose", 
      "erythropoietin", 
      "stem cell factor", 
      "interleukin", 
      "Interleukin-3", 
      "stem cell technology", 
      "Vancouver", 
      "BC", 
      "Canada", 
      "Germany", 
      "microbial culture", 
      "anaerobic bacteria", 
      "contamination", 
      "culture medium", 
      "fa", 
      "Durham", 
      "NC", 
      "flow cytometry", 
      "expression", 
      "antigen", 
      "Becton Dickinson", 
      "flow cytometric assay", 
      "monoclonal antibody", 
      "Fluorescein-5-isothiocyanate", 
      "San Jose", 
      "CA", 
      "protein complex", 
      "Clone Cell", 
      "PE", 
      "APC", 
      "KDR", 
      "determination", 
      "blood sample", 
      "tube", 
      "total volume", 
      "phosphate", 
      "Pb", 
      "bovine serum albumin", 
      "antibody", 
      "dark", 
      "wash", 
      "room temperature", 
      "BD", 
      "recording", 
      "lymphocyte", 
      "monocyte", 
      "Automatic Data Processing", 
      "FACS", 
      "viability", 
      "amino", 
      "molecular probe", 
      "Eugene", 
      "hill", 
      "anesthesia", 
      "disinfection", 
      "suspension", 
      "needle", 
      "compartment", 
      "leg", 
      "foot", 
      "baseline assessment", 
      "Pain Measurement", 
      "scale", 
      "drug use", 
      "management", 
      "evolution", 
      "pain management"
    ], 
    "name": "Autologous Immunomagnetic Selected cd133+ Cells in the Treatment of No-option Critical Limb Ischemia: Clinical and Ceus Assessed Results.", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01595776"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00012.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.419425.f", 
        "type": "Organization"
      }
    ], 
    "startDate": "2009-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/s12967-015-0697-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052702381", 
          "https://doi.org/10.1186/s12967-015-0697-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01595776"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01595776'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01595776'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01595776'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01595776'


 

This table displays all metadata directly associated to this object as RDF triples.

277 TRIPLES      16 PREDICATES      270 URIs      263 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01595776 schema:about anzsrc-for:3053
2 schema:description Aim: to value the safety and efficacy of local intramuscular administration of immunoselected autologous endothelial progenitor cells in the treatment of critical limb ischemia in patients without revascularization options. Primary goal: to value the feasibility of mobilization, harvesting, immunoselection and auto transplantation of endothelial progenitor cells. Secondary goal: to value the efficacy of local administration of autologous endothelial progenitor cells in the treatment of critical limb ischemia Detailed Description Type of the study. Prospective single centre not randomized. Aim of the study. To assess the safety, feasibility and efficacy of local intramuscular administration of autologous selected CD 133+ cells in patients suffering from CLI. All the patients enrolled were suffering from CLI according to the TASC 2 definitions and had no revascularization option, on the basis of contrast CT or angiography imaging. A detailed informed consent, approved by our EC, had been required. An age lower than 18 years and upper than 70 years because of a poor marrow responsiveness to drug simulation in elderly people Clinical unsteadiness of the CLI, such as gangrene requiring major amputation and a poor life expectancy were introduced as exclusion criteria for supposed latency of the EPCs action. Severe systemic illness was judged to increase the risk of the marrow stimulation. Patients with allergic diathesis, child-bearing age, previous EPCs muscular implant, previous medical experimental protocol and any conflict of interest with the study were excluded. Patients: we enroll patients with a history of Rutherford stage 4 (rest pain) or 5 (small ischemic lesions) PAD. All the patients have previous (contrast CT, MR or angiography) vascular imaging excluding revascularization options, both endovascular and open and encountered the enrolment and exclusion criteria. Every patient undergo routine physical and instrumental examination including electrocardiogram, chest X-ray and blood sample analysis. Younger patients met the Buerger disease criteria, whereas others had pure atherosclerotic lesions. CEUS Imaging Protocol. Two operators (F.C. and A.G., with 20 and 3 years experience, respectively) who are blinded to treatment perform contrast-enhanced US for all patients. Two US scanner (Philips iU22 (Bothell, WA, USA) with linear array L9-3 transducer and GE Logiq e9 (GE Healthcare, Milwaukee, WI, USA) with linear array L6-9 transducer are used. The imaging parameters are: reduced transmit power (mechanical index <0.06), at approximately 7-10 frames per second and one focus well below the level of the target to ensure a more uniform pressure field. Dual-mode presentation of a grayscale image side-by-side with the contrast image facilitated real-time identification of anatomic structures and ROI selection. Image loops of approximately 60 seconds were acquired. Effort was made to have a uniform gain across the image and to avoid gain saturation. The TGC (time gain compensation) was set such that before contrast arrival a uniform black image was shown. A vial of contrast agent (SonoVue BR1; Bracco, Milan, Italy) is prepared at a concentration of about 2x108 sulfur hexafluoride-filled microbubbles per milliliter, according to the manufacturer's recommendations. Prior to each injection, microbubbles are resuspended by shaking the vial. The position of the probe is recorded for each patient in order to maintain the same position during follow up. The contrast injection consists of an intravenous bolus of 4.8 ml of contrast agent injected in antecubital vein in 2 seconds followed by a saline flush of 5 ml. The injection is made with the patient supine and after 10 minute of rest to avoid exercise related micro-vascular dilatation. The radiologist maintains a constant image plane with the aid of the tissue (fundamental image) of the "Contrast Side/Side" imaging mode. Image analysis. The image loops are transferred to a personal computer for further analysis. The main image analysis tasks are: a) identification of tibialis anterior artery (TAA) area, b) selection of a representative region of normal tibialis anterior muscle (TAM) and c) formulation of time-intensity curves. Two manually defined region of interest (ROI), 2 cm and 4 cm sided-squares, are placed, respectively, over the tibialis anterior muscle with no evidence of arterial branches, over tibialis anterior artery and over a small tibialis arterial branch. The ROIs are placed in the same anatomical position for each patient to avoid unwanted differences during follow up examinations. A time/intensity curve (TIC) is obtained for each ROI. From an analysis of CEUS time-intensity curves, we compute regional blood flow (RBF) and volume (RBV). Time-intensity curves are extracted using commercial quantification software (QontraXt v.3.60, AMID, Rome, Italy). This software allows manual region of interest (ROI) selection, measurement of the selected ROI area and provides linear data for the time-intensity curves. For the ROI in the normal ATM effort is made to place the region in an area without large vessels. The ROI of the ATA is a 2 cm square area and the ATM ROI is a 4 cm square area. Time-intensity curves are obtained by computing the mean intensity of pixels comprised within the ROI at each time point. For each image loop are calculated: - RBV which consists in the total amount of contrast media within the selected ROI, in a period of time. Due to the characteristics of US contrast media, it reflects the quantity of blood in a defined region. It is directly related to the area under the curve (AUC). - RBF that is in direct ratio to perfusion in a given ROI. It consist in the Contrast Media flow (related to the Blood Flow) in a selected ROI. It is related to the Mean Transit Time. Marrow stimulation. Human recombinant granulocyte colony-stimulating factor (rhGCSF) is administered subcutaneously for 4-5 consecutive days at a dosage of 10 µg/kg daily, split in 2 doses. Starting from the third day of mobilization, the CD133+ cell count is monitored daily by cytofluorimetric analysis on a 2 ml sample obtained from the patients' peripheral blood. The minimum CD133+ cell count acceptable for leukapheresis (LKF) collection was 10/µl. Patients are monitored for any G-CSF related side effects. Leukapheresis collection. A single LKF collection is planned for each patient using a third generation cell separator device (Spectra Cobe, Lakewood, CO), processing at least 2.5 blood volumes according to our internal protocol for stem cell collection. Patients are monitored for blood pressure and heart rate during the entire collection procedure. Immediately after LKF a sample from patient's peripheral blood is taken for haemocytometric analysis to evaluate platelet count and Hb levels. Each leukapheresis collection is diluted with 10% acide citrate dextrose (ACD-A) and maintains overnight at 4°C before immunomagnetic cell selection. A sample of 2 ml from each LKF bag is taken for cytofluorimetric analysis. Four hours after LKF collection coagulation parameters, electrolyte levels and hemocytometric analysis is evaluated. Immunomagnetic cell selection. CD133 immunomagnetic cell selections are performed the day after LKF collection using the Clini-MACS (Miltenyi Biotec) device according to the manufacturer's standard protocol. Briefly, CliniMACS CD133 reagent (formed by super paramagnetic particles composed of iron oxide and dextran conjugated to murine monoclonal antibodies) is added to the cells for incubation. The product is subsequently washed by dilution with buffer (CliniMACS PBS-EDTA buffer supplemented with 0.5% human serum albumin) and the cell bag is hung on the device for the automated selection of CD133 labeled cells. A sample of 2 ml from the positive fraction is taken for cytofluorimetric analysis. Quality controls. Clonogenic assays. A sample taken from the CD133 cell positive fraction after each immunomagnetic cell selection procedure is seeded for short term (14 days) clonogenic assays. A standard mixture of methylcellulose plus recombinant human erythropoietin, rh stem cell factor (SCF), rhGM-CSF, and rh interleukin-3 (IL-3) is employed (Stem Cell Technologies, Vancouver, BC, Canada; MACS Media, Miltenyi Biotec GmbH, Bergisch Gladbach,Germany). Microbial cultures. Microbial cultures on the immunoselection waste bag containing the negative fraction are carried out to detect aerobic-anaerobic bacteria and fungal contamination. A sample of 10ml is inoculated in the culture medium (Bact/Alert FA and BacT/Alert FN, Organon Teknika Corp., Durham, NC) and incubated for 10 days at 37°C. Cytofluorimetric analysis. Samples obtained from peripheral blood before mobilization with G-CSF, at time of leukapheresis and after immunomagnetic cell selection are analyzed by flow cytometry to evaluate the expression of specific stem cell and endothelial antigens. Becton Dickinson FACSCanto was employed for all flow cytometric assays with a lyse no-wash technique, using the following monoclonal antibodies: anti-CD45 fluorescein isothiocyanate (FITC) (Becton Dickinson, San Jose, CA), anti-CD34 Peridinin-chlorophyll-protein complex (PerCP) (8G12 clone, Becton Dickinson), anti-CD133 phycoerythrin (PE) (AC133 clone, Miltenyi Biotec) and anti-VEGF-R2 allophycocyanin (APC) (R&D systems). Whole blood is processed following the instructions for VEGF-R2 (KDR) determination. Each blood sample is transferred to a 50 ml falcon tube and brought to a total volume of 30 ml by adding ammonium phosphate containing lysis buffer (Becton Dickinson). After a lysis period of 5 minutes PB is centrifuged at 500g for 5 minutes and washed two times with PBS containing 0,5% bovine serum albumin (BSA). 100 µl of each sample are then transferred in a BD tube for cytometric analysis and incubated for 15 minutes with 1µg/105 cells IgG in order to block all nonspecific sites. 50 µl of the IgG blocked sample are incubated with 20 µl of anti-VEGF-R2 antibody for 30 minutes at 4°C in the dark and then washed twice with PBS. At the end of the last wash step, 10 µl of each of the other antibodies (anti-CD45, anti-CD34, anti-CD133) are added and incubated 10 minutes at room temperature in the dark. Each sample is acquired with BD FACSCanto recording 100.000 events inside the lymphocyte plus monocyte gate. Data files are analyzed with FACS Diva 6.1 software. Viability is assessed using 7-amino-actinomycin D (7-AAD) (Molecular Probes, Eugene, OR). A sample for Hill and EBM2 clonogenic assays is taken from patient's peripheral blood before and after mobilization (at time of LKF collection). Implant procedure. After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot. Baseline assessment and follow up. Pain assessment is carried out with a personal scale of 3 degrees (mild, moderate and severe) and the pain killing drugs use monitoring. Ischemic lesions are treated weekly by a wound management skilled nurse. Preoperative and at 3, 6 and 12 months after the implant are assessed CEUS, lesion evolution and pain management.
3 schema:endDate 2011-12-01T00:00:00Z
4 schema:keywords ACD
5 APC
6 ATM
7 Attention
8 Automatic Data Processing
9 BC
10 BD
11 Becton Dickinson
12 CA
13 CD133
14 CD133+ cell
15 CEUS
16 CO
17 Canada
18 Clone Cell
19 Durham
20 EC
21 EPCs
22 Electrocardiography
23 Equipment and Supply
24 Eugene
25 FACS
26 Fluorescein-5-isothiocyanate
27 GE Healthcare
28 Ge
29 Germany
30 Granulocyte Colony-Stimulating Factor
31 Hb
32 Interleukin-3
33 Italy
34 KDR
35 MR
36 Microcomputer
37 Milan
38 Milwaukee
39 NC
40 PE
41 Pain Measurement
42 Pb
43 Philip
44 Rome
45 Rutherford
46 San Jose
47 Time
48 USA
49 Vancouver
50 WA
51 WI
52 Younger
53 age
54 amino
55 amputation
56 anaerobic bacteria
57 anatomic structure
58 anesthesia
59 angiography
60 antibody
61 antigen
62 area under the curve
63 artery
64 atherosclerotic lesion
65 bag
66 baseline assessment
67 blood
68 blood flow
69 blood pressure
70 blood sample
71 blood volume
72 bolus
73 bovine serum albumin
74 branch
75 buffer
76 cell
77 cell selection
78 characteristic
79 chest x-ray
80 child-bearing age
81 clonogenic assay
82 cm
83 coagulation
84 collection
85 collection procedure
86 compartment
87 conflict
88 contamination
89 contrast
90 contrast agent
91 contrast medium
92 criterion
93 critical limb ischemia
94 culture medium
95 curve
96 dark
97 defined region
98 definition
99 detailed description
100 determination
101 dextran
102 difference
103 dilatation
104 dilution
105 disinfection
106 dosage
107 dose
108 drug use
109 dual mode
110 efficacy
111 elderly people
112 electrolyte
113 endothelial progenitor cell
114 enrollment
115 erythropoietin
116 evidence
117 evolution
118 examination
119 exclusion criterion
120 experimental protocol
121 expression
122 fa
123 feasibility
124 flow
125 flow cytometric assay
126 flow cytometry
127 foot
128 formulation
129 fraction
130 frame
131 fundamental
132 gangrene
133 harvesting
134 heart rate
135 hill
136 history
137 human serum albumin
138 image analysis
139 image plane
140 imaging mode
141 imaging parameter
142 imaging protocol
143 immunoselection
144 implant
145 incubation
146 index
147 informed consent
148 injection
149 intensity
150 interleukin
151 intramuscular
152 iron oxide
153 ischemic lesion
154 labeled cell
155 large vessel
156 latency
157 leg
158 leukapheresis
159 life expectancy
160 linear array
161 local administration
162 loop
163 lymphocyte
164 management
165 manufacturer
166 mean transit time
167 measurement
168 methylcellulose
169 microbial culture
170 microbubbles
171 mixture
172 mobilization
173 molecular probe
174 monoclonal antibody
175 monocyte
176 murine monoclonal antibody
177 muscle
178 needle
179 operator
180 option
181 pad
182 pain management
183 particle
184 patient
185 perfusion
186 period
187 peripheral blood
188 phosphate
189 pixel
190 platelet count
191 power
192 pressure field
193 primary goal
194 probe
195 processing
196 product
197 protein complex
198 protocol
199 quality control
200 quantification
201 quantity
202 radiologist
203 ratio
204 reagent
205 real-time identification
206 recommendation
207 recording
208 region interest
209 region of interest
210 regional blood flow
211 representative
212 responsiveness
213 rest
214 revascularization
215 risk
216 room temperature
217 safety
218 saline
219 same position
220 sample
221 sample analysis
222 saturation
223 scale
224 scanner
225 secondary goal
226 selection
227 selection procedure
228 short term
229 side effect
230 side-by-side
231 simulation
232 single center
233 software
234 square
235 standard protocol
236 stem cell
237 stem cell factor
238 stem cell technology
239 stimulation
240 suspension
241 systemic illness
242 target
243 third generation
244 time point
245 tissue
246 total amount
247 total volume
248 transducer
249 transplantation
250 tube
251 uniform
252 vascular imaging
253 vein
254 viability
255 vial
256 volume
257 wash
258 schema:name Autologous Immunomagnetic Selected cd133+ Cells in the Treatment of No-option Critical Limb Ischemia: Clinical and Ceus Assessed Results.
259 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01595776
260 schema:sdDatePublished 2019-03-07T15:24
261 schema:sdLicense https://scigraph.springernature.com/explorer/license/
262 schema:sdPublisher Nebc970b9c8ec436ab09ae785af493dee
263 schema:sponsor https://www.grid.ac/institutes/grid.419425.f
264 schema:startDate 2009-01-01T00:00:00Z
265 schema:subjectOf sg:pub.10.1186/s12967-015-0697-4
266 schema:url https://clinicaltrials.gov/show/NCT01595776
267 sgo:license sg:explorer/license/
268 sgo:sdDataset clinical_trials
269 rdf:type schema:MedicalStudy
270 Nebc970b9c8ec436ab09ae785af493dee schema:name Springer Nature - SN SciGraph project
271 rdf:type schema:Organization
272 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
273 rdf:type schema:DefinedTerm
274 sg:pub.10.1186/s12967-015-0697-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052702381
275 https://doi.org/10.1186/s12967-015-0697-4
276 rdf:type schema:CreativeWork
277 https://www.grid.ac/institutes/grid.419425.f schema:Organization
 




Preview window. Press ESC to close (or click here)


...